ChiCTR-IPC-15006617
结束
/
/
/
2015-06-17
/
/
knee osteoarthritis
葡萄糖注射治療對退化性膝關節炎的效用
葡萄糖注射治療對退化性膝關節炎的效用
葡萄糖注射治療對退化性膝關節炎的效用
随机平行对照
其它
Randomized
Double-blind
Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong
/
38
/
2015-06-30
1990-01-01
/
1. To be aged from 45 to 75 years old; 2. Diagnosis of knee OA based on clinical criteria as defined by the American Rheumatology Association; 3. Have experienced moderate to severe anterior knee pain for at least 3 months, defined as a score of 3 or more (0-6 ordinal response scale) on the question "What is the average level of your left/right knee pain?" 4. Failed 6 months of usual care.；
请登录查看1. History of corn allergy; 2. Previous operation either open or arthroscopic, on the referring knee; 3. Pregnancy; 4. Body mass index >=35 kg/m2; 5. Patients on anti-coagulant therapy; 6. Prior knee prolotherapy; 7. Any knee injections within 3 months; 8. Inflammatory or post-infectious knee arthritis; 9. Significant effusion as defined by a balotteable patella; 10. Co-morbidity severe enough to prevent participation in the study protocol like attendance at scheduled injection appointments.；
请登录查看Professor Regina Wing Shan SIT
/
Professor Regina Wing Shan SIT的其他临床试验
Division of Family Medicine and Primary Health Care, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04